Letting your mind wander — if focused on the right things — can be a good use of your business day. Getty Images

The mind is prone to wander. Commonly known as daydreaming – the state of mental disconnection from the task at hand – it can take up as much as half of the typical workday.

Some research suggests this may be a good thing. Wandering minds help us adapt to problems, the reasoning goes, because by briefly changing our focus, we can solve problems more creatively.

That's not to say daydreaming is always benign. We prefer that the E.R. surgeon focus on the operation. The boxer is best off concentrating on slipping a punch. In general, when it comes to one-time tasks, daydreaming is suboptimal.

Rice Business professor Erik Dane has tried to bridge these two different views of mind wandering at work. In a recent paper, Dane suggests that while daydreaming can undermine productivity, it is also a critical problem-solving tool.

In an extensive literature review, Dane explored a series of questions about how mind wandering works. Based on current research, he concluded that a wandering mind can be positive if where it wanders is work related. Such a wandering mind helps employees conceive of possibilities not previously considered.

There's a vast difference between daydreaming and plain distraction, Dane notes. Turning your attention from composing a strategy memo to answering an annoying text from the cable company is not mind- wandering – it's digression (or multitasking). And when you look up from cooking dinner to see your neighbor hacking down your bamboo, that's not mind wandering – it's annoyance.

Mind wandering implies instead that your thoughts have drifted from the present altogether. From a neuroscience perspective, it is a journey into the brain's "default network" – a mode of functioning that occurs when the mind is not consumed with demands in one's surroundings. When you're driving home and forget to stop at the grocery store because you're envisioning your imminent vacation to Barcelona, that's mind wandering.

According to Dane, mind wandering can be good for businesses – if it revolves around work issues. Wandering on your downtime may steal a few moments from your personal life, but it's a powerful way to take advantage of relaxation to solve professional problems.

There are other ways mind wandering can be positive. Think for a moment about James Thurber's classic character Walter Mitty, whose mind is constantly taking flights of fancy. He's not as hapless as he might seem. Outside the work context, Dane writes, mind wandering allows us to conceive of possibilities, scenarios and images disconnected from time and, in some cases, basic feasibility. But it's the quintessential first step of innovation.

Another type of mind wandering involves movement through time. Past, present and future mingle. As a manager mulls strategies for handling a problem employee, her thoughts may slide to a time when she too was considered a problem at work. The memories, context and details swirling through her mind may redirect her toward a less-obvious solution to the conundrum.

But mind wandering is not all positive. It can easily devolve into thoughts and feelings that inhibit performance. The stress from negative daydreams may even discourage a worker from focusing on a task – or doing it at all.

To facilitate job performance, Dane writes, it's important to keep in mind your work goals. It's also essential to stay positive – even as you let your thoughts drift. In other words, focus on goals, their associated tasks and sub-goals, and steer clear of distracting worries, which can keep you from finding solutions.

The more you succumb to anxiety, Dane warns, the more the associated cognitive effects will undermine your performance. It's a skill, in other words: relax enough to be creative, yet keep the negative thoughts in check. Like getting comfortable with new software or maximizing production on an assembly line, productive mind wandering is learnable, Dane promises. And unlike a computer or a car factory, the tools within our brains only grow more productive with use.

------

This article originally appeared on Rice Business Wisdom.

Erik Dane is an associate professor of management at the Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.